.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
Cerilliant
Cipla
Dow
Medtronic
Colorcon
US Army
Argus Health
UBS

Generated: June 25, 2017

DrugPatentWatch Database Preview

TYZEKA Drug Profile

« Back to Dashboard

Which patents cover Tyzeka, and what generic Tyzeka alternatives are available?

Tyzeka is a drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this drug.

This drug has fifty-four patent family members in twenty-one countries.

The generic ingredient in TYZEKA is telbivudine. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the telbivudine profile page.

Summary for Tradename: TYZEKA

Patents:7
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list44
Clinical Trials: see list5
Patent Applications: see list794
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TYZEKA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
TYZEKA
telbivudine
TABLET;ORAL022011-001Oct 25, 2006RXYesYes7,858,594► SubscribeYY ► Subscribe
Novartis
TYZEKA
telbivudine
TABLET;ORAL022011-001Oct 25, 2006RXYesYes6,444,652► Subscribe ► Subscribe
Novartis
TYZEKA
telbivudine
TABLET;ORAL022011-001Oct 25, 2006RXYesYes6,569,837► Subscribe ► Subscribe
Novartis
TYZEKA
telbivudine
SOLUTION;ORAL022154-001Apr 28, 2009DISCNNoNo6,566,344► Subscribe ► Subscribe
Novartis
TYZEKA
telbivudine
TABLET;ORAL022011-001Oct 25, 2006RXYesYes6,395,716► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TYZEKA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,290,533.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
2,011,195,922► Subscribe
7,304,043.beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
7,323,451Crystalline and amorphous forms of beta-L-2'-deoxythymidine► Subscribe
6,946,450 .beta.-L-2'-deoxy-nucleosides for the treatment of hepatitis B► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TYZEKA

Country Document Number Estimated Expiration
Luxembourg91348► Subscribe
China1911237► Subscribe
Japan4294870► Subscribe
Cyprus1116988► Subscribe
Denmark1431304► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TYZEKA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
07/027Ireland► SubscribePRODUCT NAME: TELBIVUDINE AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/07/388/001 20070424
/2007Austria► SubscribePRODUCT NAME: TELBIVUDIN; REGISTRATION NO/DATE: EU/1/07/388/001 20070424
00286Netherlands► SubscribePRODUCT NAME: TELBIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/388/001 20070424
348Luxembourg► SubscribeCERTIFICATE NAME: TELVIDUBINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; FIRST REGISTRATION DATE: 20070424
1104436/01Switzerland► SubscribeFORMER OWNER: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, FR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
AstraZeneca
Argus Health
Healthtrust
Colorcon
Chubb
Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot